Dna X (SONM) EBIAT (2018 - 2025)
Dna X (SONM) has disclosed EBIAT for 8 consecutive years, with -$4.8 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, EBIAT fell 89.21% year-over-year to -$4.8 million, compared with a TTM value of -$33.4 million through Sep 2025, down 149.38%, and an annual FY2024 reading of -$33.6 million, down 37286.67% over the prior year.
- EBIAT was -$4.8 million for Q3 2025 at Dna X, up from -$7.5 million in the prior quarter.
- Across five years, EBIAT topped out at $527000.0 in Q3 2023 and bottomed at -$21.6 million in Q4 2024.
- Average EBIAT over 5 years is -$5.2 million, with a median of -$4.2 million recorded in 2022.
- The sharpest move saw EBIAT soared 132.77% in 2023, then crashed 1497.49% in 2024.
- Year by year, EBIAT stood at -$11.7 million in 2021, then skyrocketed by 91.11% to -$1.0 million in 2022, then fell by 29.85% to -$1.4 million in 2023, then plummeted by 1497.49% to -$21.6 million in 2024, then skyrocketed by 78.01% to -$4.8 million in 2025.
- Business Quant data shows EBIAT for SONM at -$4.8 million in Q3 2025, -$7.5 million in Q2 2025, and $458000.0 in Q1 2025.